IP Library Granted Patent US 10,272,055
Granted Patent B2
US 10,272,055 · App. 14/641,122 · Granted Apr 30, 2019

Therapeutic compounds and methods

Inventors: David A. Potter (Minneapolis, MN); Zhijun Guo (Minneapolis, MN); Elizabeth Amin (Minneapolis, MN); Gunda Georg (Minneapolis, MN); Tom Poulos (Irvine, CA); Irina Sevrioukova (Irvine, CA)
Assignees: Regents of the University of Minnesota; The Regents of the University of California
A61K31/155A61K31/417A61K31/426A61K31/4409A61K45/06C07C279/26C07D213/36C07D233/64C07D277/28C12N9/0073C07K2299/00C07K2319/21
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,272,055
App. No.
14/641,122
Granted
Apr 30, 2019
Kind
B2
Abstract

Biguanide compounds and salts thereof are disclosed. Also disclosed are pharmaceutical compositions and therapeutic methods for treating certain diseases including cancer such as breast cancer.

Claims (8)

1. A method for treating breast cancer occurrence or recurrence in a human patient in need thereof, comprising:

1) obtaining a biological sample comprising breast cancer cells from the patient;

2) detecting whether N1-hexyl-N5-benzyl biguanide (HBB):

or a pharmaceutically acceptable salt thereof, inhibits oxidative phosphorylation and glycolysis in the breast cancer cells by contacting the sample with HBB, or a pharmaceutically acceptable salt thereof, and measuring the oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) in the breast cancer cells;

3) identifying the human patient as having a breast cancer that is treatable with HBB when inhibition of OCR and ECAR is detected, as compared to OCR and ECAR in the breast cancer cells contacted with a negative control compound; and

4) administering to the human patient in need thereof a therapeutically effective amount of HBB, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the breast cancer is estrogen receptor positive (ER+), human epidermal growth factor receptor 2 (HER2) negative breast cancer.

3. The method of claim 1 , further comprising administering paclitaxel to the patient.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2019
From: POULOS, TOM; SEVRIOUKOVA, IRINA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 047896/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2015
From: POTTER, DAVID A.
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 037377/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2015
From: AMIN, ELIZABETH
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 036789/0952 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2015
From: GEORG, GUNDA
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 036789/0972 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2015
From: GUO, ZHIJUN
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 036789/0984 →
CONFIRMATORY LICENSE Recorded Apr 21, 2015
From: UNIVERSITY OF MINNESOTA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035466/0931 →
Continuity (2)
Provisional Application 61949218 · Mar 6, 2014
Related Publication 20150342909A1 · Dec 3, 2015